[BioS] QuadMedicine presents research results on its 'hair-loss microneedle' platform
Predicted impact: Low
Early research results on hair-loss platform; small and vague.
QuadMedicine쿼드메디슨
464490 · KOSDAQ · ₩464490 · 쿼드메디슨
₩4,090▼ ₩100 (2.39%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −76.80%
- Market cap
- ₩47B
- Enterprise value
- ₩37B
- P/E
- —
- P/B
- 1.9×
- Dividend yield
- 0.0%
- ROE
- −40.6%
- Net margin
- −139.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−84.9% from the high
₩3,850Today: ₩4,030 – ₩4,300₩27,150
Returns
- 1W−8.9%
- 1M−8.0%
- 3M−25.4%
- 6M−70.8%
- YTD−73.8%
- 1Y—
- Volume today
- 28,223
- 0.6× the 20-day average
- Traded today
- ₩116M
- Listed shares
- 11,507,963
- EPS (12 months)
- −₩866
- Earnings yield −21.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.IPOListed Dec 12, 2025 at ₩15,000IPO details →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Research presentation is positive news, but there is little detail about its impact. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-7.9% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
QuadMedicine stock overview
QuadMedicine (쿼드메디슨, KRX: 464490) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops microneedle drug delivery platforms that reformulate and change the administration route of already-approved medicines to improve effectiveness and patient adherence. Its shares closed at ₩4,090 on Oct 27, 2026, down 2.39% on the day, giving it a market value of ₩47B.
Key facts
- Market cap
- ₩47B
- Sector
- Biotech & Pharma
- Latest price change
- −2.39%
- As of
- Oct 27, 2026
- Main business
- The company develops microneedle drug delivery platforms that reformulate and change the administration route of already-approved medicines to improve effectiveness and patient adherence.
Quick answers about QuadMedicine
- What does QuadMedicine do?
- The company develops microneedle drug delivery platforms that reformulate and change the administration route of already-approved medicines to improve effectiveness and patient adherence. It offers these platforms through a contract development and manufacturing (CDMO) model, working with pharmaceutical companies from early feasibility studies through clinical-stage development and later large-scale manufacturing. Its core technologies are S-MAP, C-MAP and P-MAP, which are aimed at synthetic drugs, biopharmaceuticals and vaccines, and its revenue comes mainly from technology fees from domestic pharmaceutical clients.
- What is the market cap of QuadMedicine?
- The market capitalisation of QuadMedicine was ₩47B at the close on Oct 27, 2026.
- Who are the largest shareholders of QuadMedicine?
- According to the latest official filings, the largest reported holders are Baek Seung-gi (19.62%, as of Oct 26, 2026); Kiwoom Investment (6.74%, as of Dec 19, 2025); Shinhan Venture Investment (4.31%, as of Feb 6, 2026).
- When is the next earnings report from QuadMedicine?
- Korean companies rarely announce results dates in advance. Based on when QuadMedicine filed the same report in past years, its next 3q results is expected between Nov 7, 2026 and Nov 29, 2026.
Company profile
The company develops microneedle drug delivery platforms that reformulate and change the administration route of already-approved medicines to improve effectiveness and patient adherence. It offers these platforms through a contract development and manufacturing (CDMO) model, working with pharmaceutical companies from early feasibility studies through clinical-stage development and later large-scale manufacturing. Its core technologies are S-MAP, C-MAP and P-MAP, which are aimed at synthetic drugs, biopharmaceuticals and vaccines, and its revenue comes mainly from technology fees from domestic pharmaceutical clients.
Written by AI from the company's latest annual report.
- Korean name
- 쿼드메디슨
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 백승기
- Founded
- Dec 2016
- Listed
- Dec 2025
- Listed shares
- 11,507,963
- Fiscal year ends
- Month 12
- Website
- www.quadmedicine.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Insider shareholding reportOct 26, 2026
- Major management matter relevant to investorsSep 14, 2026
- Amended: Insider shareholding reportAug 31, 2026
- Insider shareholding reportAug 31, 2026
- Insider shareholding reportAug 31, 2026
Titles in Korean until English translations are added.
Also known as: QuadMedicine / 쿼드메디슨 / 464490 / KRX:464490
Source: KRX statistical information